NASDAQ:CEMI Chembio Diagnostics (CEMI) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free CEMI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.45▼$0.4650-Day Range$0.33▼$0.4652-Week Range$0.19▼$1.24Volume351,642 shsAverage Volume661,416 shsMarket Capitalization$16.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Chembio Diagnostics alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Chembio Diagnostics Stock (NASDAQ:CEMI)Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… CEMI Stock News HeadlinesApril 17, 2024 | finance.yahoo.comANY LAB TEST NOW Forms Strategic Partnership with ChembioNovember 2, 2023 | morningstar.comQuest Diagnostics Inc DGXApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 24, 2023 | marketwatch.comQualigen Therapeutics Sells FastPack Diagnostics Business to ChembioApril 27, 2023 | finance.yahoo.comBiosynex Completes Acquisition of Chembio Diagnostics, Inc.April 27, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Arbutus Biopharma (ABUS) and Chembio Diagnostics (CEMI)April 20, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with BiosynexApril 19, 2023 | finance.yahoo.comChembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 14, 2023 | msn.comChembio Diagnostics And 2 Other Stocks Under $1 Insiders Are Aggressively BuyingApril 10, 2023 | finance.yahoo.comChembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023April 3, 2023 | finance.yahoo.comChembio’s CEO Letter to StockholdersMarch 21, 2023 | finance.yahoo.comChembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023March 15, 2023 | finance.yahoo.comBiosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.March 15, 2023 | finance.yahoo.comChembio Announces Letter to Stockholders Regarding Tender OfferFebruary 24, 2023 | finance.yahoo.comChembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis SystemFebruary 8, 2023 | benzinga.comMoore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law FirmFebruary 2, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. BuyoutFebruary 1, 2023 | finance.yahoo.comFrench Rapid Testing Company Scoops Up Chembio Diagnostics For $17MJanuary 31, 2023 | finance.yahoo.comBiosynex and Chembio Diagnostics Announce Definitive Acquisition AgreementJanuary 21, 2023 | seekingalpha.comCEMI Chembio Diagnostics, Inc.January 7, 2023 | forbes.comChembio DiagnosticsNovember 28, 2022 | finance.yahoo.comChembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis SystemNovember 6, 2022 | seekingalpha.comChembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comChembio Diagnostics Reports Third Quarter 2022 Financial ResultsOctober 20, 2022 | finance.yahoo.comChembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022September 6, 2022 | finance.yahoo.comChembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm AssaySee More Headlines Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CEMI CUSIPN/A CIK1092662 Webwww.chembio.com Phone(631) 924-1135Fax631-924-2065Employees337Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,290,000.00 Net Margins-47.03% Pretax Margin-46.96% Return on Equity-113.57% Return on Assets-38.22% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.04 Sales & Book Value Annual Sales$48.34 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.95Miscellaneous Outstanding Shares36,726,000Free Float35,514,000Market Cap$16.71 million OptionableNot Optionable Beta1.85 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesRichard L. EberlyPresident, Chief Executive Officer & DirectorPaul J. AngelicoChief Operations Officer & Executive VPLawrence J. SteenvoordenChief Financial Officer, Secretary & Executive VPJavan EsfandiariExecutive VP, Chief Science & Technology OfficerAtif RizviVice President-FinanceKey CompetitorsNeuroBo PharmaceuticalsNASDAQ:NRBOAvalo TherapeuticsNASDAQ:AVTXAytu BioPharmaNASDAQ:AYTUPieris PharmaceuticalsNASDAQ:PIRSTalpheraNASDAQ:TLPHView All CompetitorsInsidersCredit Advisors Ll PerceptiveBought 39,506 shares on 4/24/2023Total: $17,777.70 ($0.45/share) CEMI Stock Analysis - Frequently Asked Questions How were Chembio Diagnostics' earnings last quarter? Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The firm had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%. During the same period last year, the company earned ($0.28) earnings per share. What other stocks do shareholders of Chembio Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK). This page (NASDAQ:CEMI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chembio Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
